sumithion 1000ec insecticide
sumitomo chemical australia pty. limited - fenitrothion - emulsifiable concentrate - fenitrothion organophosphorus active 1000.0 g/l - insecticide - apple | broiler poultry house,litter,wall & roof | cabbage | cereal crop | cherry | feed bin | feed shed | grain storage area an - australian plague locust | black beetle | corbie | flour beetles | grain weevil | indian meal moth | lesser grain borer | lesser mealworm | migratory locust | oxycanus grass grub | pasture cockchafer | sawtoothed grain beetle | sitona weevil | spur-throated locust | stored grain insect pests | tropical warehouse moth | underground grass grub | wingless grasshopper | winter corbie | black beetle | darkling beetle | grain borer | litter beetle | nomadacris guttulosa | sitophilus granarius | sitophilus oryzae | sitophilus zeamais | tribolium castaneum | tribolium confusum | tribolium spp.
sumitomo rizolex 100d fungicide
sumitomo chemical australia pty. limited - tolclofos-methyl - dust - tolclofos-methyl organophosphorus active 100.0 g/kg - fungicide - cotton seed | potato seed piece - rhizoctonia solani | damping off | hypocotyl rot
poolkare chemicals tiger-a bromine tablets
wobelea pty limited - bromine present as bromo-chloro-dimethylhydantoin; chlorine present as bromo-chloro-dimethylhydantoin - tablet (inc. pellet, bolus, suppository, capsule) - bromine present as bromo-chloro-dimethylhydantoin mineral-bromine active 650.0 g/kg; chlorine present as bromo-chloro-dimethylhydantoin mineral-chlorine active 280.0 g/kg - pool chlorine - spa | swimming pool | outdoor spa | spa pools - algae | bacteria
nufarm bond adjuvant
nufarm australia limited - synthetic latex; alcohol ethoxylate - liquid - synthetic latex ungrouped active 450.0 g/l; alcohol ethoxylate emulsifiers & surfactants active 100.0 g/l - adjuvant - agricultural chemical additive | spray activator | spreading agent | wetting agent - extender/sticker/spreader | tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank
feiba nf
takeda new zealand limited - factor viii inhibitor bypassing fraction 1000 u; ; - powder for injection with diluent - 1000 u - active: factor viii inhibitor bypassing fraction 1000 u excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.
feiba nf
takeda new zealand limited - factor viii inhibitor bypassing fraction 2500 u; ; - powder for injection with diluent - 2500 u - active: factor viii inhibitor bypassing fraction 2500 u excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.
feiba nf
takeda new zealand limited - factor viii inhibitor bypassing fraction 500 u; ; - powder for injection with diluent - 500 u - active: factor viii inhibitor bypassing fraction 500 u excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.
forteo
eli lilly and company (nz) limited - teriparatide 250 µg/ml (rhpth(1-34)); - solution for injection - 250 mcg/ml - active: teriparatide 250 µg/ml (rhpth(1-34)) excipient: glacial acetic acid hydrochloric acid mannitol metacresol sodium acetate sodium hydroxide water for injection - forteo, in combination with calcium and vitamin d, is indicated for the treatment of osteoporosis in postmenopausal women and in men at high risk of fracture.
prozac 20
eli lilly and company (nz) limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg - capsule - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg excipient: dimeticone gelatin ink iron oxide yellow patent blue v starch titanium dioxide - · depression and it's associated anxiety · bulimia nervosa · obsessive-compulsive disorder and premenstrual dysphoric disorder - a severe form of pms. diagnosis of pmdd: the essential features of pmdd are clear and established cyclicity of symptoms (occurring during the last week of the luteal phase in most menstrual cycles) such as depressed mood, anxiety, affective lability, and physical symptoms such as breast tenderness or swelling, headaches, joint or muscle pain, bloating, and weight gain. pmdd is a severe clinical entity and is distinguished from the broader premenstrual syndrome by the intensity of its symptoms (particularly mood symptoms) and the extent to which it interferes with social and/or occupational function
integrilin 0.75 mgml
merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - solution for infusion - eptifibatide 0.75 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.